Middle-east Arab News Opinion | Asharq Al-awsat

Acadia Drug Approval Could Clear Way for Axovant Dementia Therapy | ASHARQ AL-AWSAT English Archive 2005 -2017
Select Page
Media ID: 55350054


A Bermuda-based company is closely studying an imminent ruling on Acadia Pharmaceuticals Inc’s drug for Parkinson’s disease psychosis, with a similar treatment for dementia. Axovant Sciences Ltd’s experimental drug for Lewy body dementia – after Alzheimer’s, the most common form of progressive dementia – would benefit from the approval of Acadia’s drug, Axovant’s chief development officer stated.

The drug won the backing of an independent panel of experts, and thus analysts are foreseeing positive ruling in the near future, while the decision by the U.S. Food and Drug Administration is due by the 1st of May.

The target of both companies’ drugs are to treat conditions that have no specific pharmaceutical therapy approved by the FDA, noting that the drugs target the 5-HT2A receptor in the brain, which is linked with neuropsychiatric disturbances.

Dr. Lawrence Friedhoff, Axovant’s chief development officer, said approval of Acadia’s drug would open a regulatory pathway for a class of drugs that would also include his own company’s treatment, called Nelotanserin.

Since the meeting of the panel of experts on March 29, shares of Acadia and Axovant have risen about 25 percent and 17 percent respectively.

“If Acadia is successful with Nuplazid, that would have a positive read-through for Nelotanserin,” Friedhoff said in an interview. “It would suggest that we have a good chance.” Friedhoff has decades of experience in the field. A former executive at Bristol-Myers Squibb Co and Eisai Co Ltd , he has sometimes been called the ‘Father of Aricept’ for his work in developing the top-selling drug for Alzheimer’s.

Nelotanserin is being tested in two mid-stage studies to treat visual hallucinations and REM sleep behavior disorder. The earliest the drug be approved is 2019, according to Axovant.

Piper Jaffray analyst Charles Duncan said the drug’s addressable population was about quadruple that of Nuplazid as a treatment for Parkinson’s disease psychosis alone. Acadia could also test its drug on LBD patients, he added.

“Lewy body dementia is one of the most interesting, under-recognized disorders,” said Duncan. “I suspect you’ll see Acadia go there too.”